Menene CBL‑514? Shin yana ƙone kitse?
Siffa: CBL‑514 an kiransa da “allurar narkar da mai”, amma ba allura ce da ke ƙone kitse ba, ba ƙara ba, kuma ba GLP‑1 ba. Shi maganin ƙwaya ne da Caliway Biopharmaceuticals ke haɓaka, wanda aka tsara don haifar da apoptosis a cikin ƙwayoyin kitse a wurin da aka yi allura. A gwajin mataki na 2 da aka gudanar a 2025, adadin ƙashin ciki ya ragu da kusan ‑216 mL a cikin makonni 8 idan aka kwatanta da placebo, yayin da nauyin jiki bai canza ba (≈+0.02 kg). Saboda haka, sakamakon ya nuna rage kitse a ƙarƙashin fata, ba ƙone kitse gaba ɗaya ba. Saboda yawan fita daga gwaji, ƙira ɗaya‑blind, da shiga mai tallafa, dole ne a yi nazari da hankali.
CBL‑514 (wani lokaci ana rubuta shi “CL‑514”) a yanar gizo
Ana yawan ganin CBL‑514 a matsayin “allurar narkar da mai”. Wannan bayanin na da wani ɓangare na gaskiya, amma “ƙone mai” ba daidai ba ne. CBL‑514 maganin ƙwaya ne da ke ƙoƙarin haifar da apoptosis a cikin ƙwayoyin kitse a wurin da aka yi allura. Ba maganin ƙone kitse na metabolic ba, ba GLP‑1 ba, kuma ba ƙari ba ne.
Abin da takardun da aka wallafa suka nuna
Menene CBL‑514, kuma menene ba shi ba
Sunan da ya dace shine CBL‑514. “CL‑514” kuskure ne da ya bayyana a wasu takardu, kuma shine kawai lokacin da ake gani a wannan rubutu.
CBL‑514:
- Maganin ƙwaya da ake bincike wanda za a iya allura.
- Ana ba da shi a matsayin allura a ƙarƙashin fata (subcutaneous) a wurin da ake maganin. A gwajin mataki na 2, wannan wurin ya kasance ƙashin ciki.
- Masu gudanar da binciken ne ke ba da shi a cikin gwaji na klinik.
CBL‑514 ba:
- Ƙari ko maganin da ake sha.
- Samfurin da aka amince da shi ga masu amfani.
- An amince da shi ta FDA; takardar mataki na 2 da aka wallafa ba ta nuna hakan ba.
Kayan da FDA ta amince da shi don rage kitse shine ATX‑101 (deoxycholic acid), wanda aka sani da Kybella. An amince da shi ne kawai don ƙashin karkashin ƙafafu (submental fat). A yanzu CBL‑514 na ci gaba da bincike don manyan wurare kamar ƙashin ciki, amma har yanzu yana cikin matakin gwaji.
Yadda ake tunanin aikin maganin
Takardar mataki na 2 ta bayyana CBL‑514 a matsayin “maganin ƙwaya da ke haifar da lipolysis wanda ke ƙarfafa apoptosis a cikin adipocytes kuma rage ƙashin ƙasa a cikin binciken ba na mutum ba”. Waɗannan ikirarin ba na mutum ba su dogara ne a kan rahotanni na sirri daga Caliway da takardar Phase 2a da ta fito (Goodman et al., 2022). A cewar wannan bincike na farko, CBL‑514 yana toshe kinase DYRK1b da ke taimakawa rayuwar sel, sannan yana ƙara samuwar masu kashe sel kamar caspase‑3 da Bax/Bcl‑2. Wannan yana haifar da apoptosis ga adipocytes a cikin gwaje‑gwaje na in‑vitro da in‑vivo, dangane da ƙimar magani. A sauƙaƙe, manufar ita ce tura ƙwayoyin kitse a wurin da aka yi allura su mutu ta hanyar apoptosis, ba don ƙara metabolic rate ko ƙone kalori gaba ɗaya ba. Dandamalin maganin ba a bayyana shi a takardun ba, don haka duk wani ikirari game da cikakken sunan, mai karɓa, ko sinadarai na gaba ɗaya shi ne hasashe ne kawai.
Shaida daga ɗan adam: Gwajin Phase 2 na 2025
Babban bayanin ɗan adam ya zo daga gwaji da aka tsara single‑blind, placebo‑controlled, Phase 2. An gudanar da shi a cibiyoyi biyar a Amurka da Australia tsakanin Fabrairu 2022 zuwa Maris 2023, kuma an wallafa a Aesthetic Surgery Journal a 2025 (matakin shaida 2).
- Girman: Mutane 130 aka duba, 81 aka shiga, 76 aka raba (50 CBL‑514, 26 placebo), 75 aka magance.
- Ƙungiyoyi: manya masu shekaru 18‑64 da BMI tsakanin 18.5‑35 kg/m². A ƙungiyar CBL‑514, kashi 94 % mata ne.
- Magani: har zuwa allura huɗu a kowane mako 4. Kowanne magani ya ƙunshi allura 25‑50 na 2.4 mL a 2 mg/cm², har zuwa 600 mg a kowanne magani. Placebo shine normal saline.
- Ma’auni: kauri na kitse ta hanyar ultrasound a maki huɗu, an juya zuwa girma a fadin wurin magani na 300 cm².
Blindness wata ƙuntatawa ce. Ɗan takara kawai aka ɓoye. Masu bincike, ma’aikatan cibiyar, da mai tallafa sun kasance a buɗe. Caliway ta kuma shiga cikin tsara gwaji, nazarin bayanai, rubuta takarda, da yanke shawarar wallafa.
To, shin yana ƙone kitse?
Ya rage kitse a ƙasa idan aka kwatanta da placebo. Ba ya haifar da ƙone kitse gaba ɗaya ko raguwar nauyi.
Game da rage kitse a ƙasa, gwajin ya cika babban manufarsa na rasa aƙalla 150 mL na girman kitse. A binciken intention‑to‑treat (ITT):
- Mako 4 bayan ƙarshe magani: kashi 63.9 % na mahalarta CBL‑514 (23/36) suka kai aƙalla 150 mL, yayin da kashi 17.4 % na placebo (4/23) suka kai, P < .001.
- Mako 8: 69.6 % (16/23) vs 0.0 % (0/16), P < .001.
- Matsakaicin rasa: bambanci na least‑squares mean ya kasance ‑206.62 mL a mako 4 da ‑216.28 mL a mako 8.
- Mafi girma a rasa: fiye da 750 mL a wani mahalarta ɗaya.
A kan nauyin jiki, canjin matsakaici a ƙungiyar CBL‑514 ya kasance +0.45 kg a mako 4 kuma +0.02 kg a mako 8. Group na placebo ya canza da ‑0.76 kg da ‑0.26 kg. Takardar ba ta nuna canjin muhimmanci a matsakaicin nauyi ko BMI ba. Hakanan ta ce wasu mahalarta da suka ƙara fiye da 1 kg har yanzu sun nuna ragin kitse a ƙasa, duk da ba a nuna wannan bayanin ba. Wannan yanayi shine abin da za a zata daga hanya ta kashe ƙwayoyin kitse a ƙasa, ba daga ƙone kitse na metabolism ba.
Gargadi kafin a yi farin ciki
Wannan lambobi suna da kwarin gwiwa ga wani gwaji da yake farawa, amma takardar na da manyan ƙuntatawa.
- Yawan fita: Daga mahalarta 75 da aka magance, 38 suka kammala gwaji, 37 ba su kammala ba, wato 49.3 % ba su kammala. Dalilan sun haɗa da rasa hanyar bin, janye, rashin daidaiton nauyi, matsalolin jadawalin, da abubuwan rashin lafiya (mutane 4).
- Raguwar ƙima: Kashi na ITT da aka ambata ya dogara ne akan mahalarta 36 sannan 23 na CBL‑514 saboda rashin bin diddigin.
- Ƙungiyar per‑protocol ƙanana: Yawan PP mutane 30 ne kawai. Tasirin da ya fi girma (matsakaicin ‑314.70 mL a mako 4 a ƙungiyar CBL‑514) ya fito ne daga mutanen da suka ci gaba da bin hanya da kuma daidaiton nauyi, don haka yana ba da kyakkyawan hangen nesa ga maganin.
- Tsarin bincike mai ƙarfi: Ba a yi amfani da ƙididdigar ƙarfi ta hanyar da ta dace ba, kuma ba a daidaita sakamakon don gwaje‑gwajen da yawa ba.
- Populashen kankane: Mahalarta mafi yawa mata ne kuma farar fata.
- Volume da ultrasound ya ƙirƙira: An ƙirƙiri girma ta hanyar tsari na cuboid daga kaurin ultrasound, ba a auna shi kai tsaye ba.
Masu rubutu suna kwatanta sakamakon da gwaje‑gwajen cryolipolysis kuma suna cewa alamar “ta fi girma”, kuma suna kwatanta sakamako da liposuction. Wadannan ra'ayoyi ne na masu rubutu. Hanyoyin auna daban‑daban ne, kuma babu gwajin kai‑tsaye da CoolSculpting ko liposuction. Zaton marasa laushi na fata da aka gani a hotunan bayan magani ya fito ne daga hoton, ba daga ma'aunin laushi na zahiri ba.
An tantance lafiyar ta hanyar abubuwan da suka faru, gwajin jini, sigogin rayuwa, ECG, duba jiki, da martani a wurin allura. Masu karatu da ke damuwa da tsaron jiki ya kamata su karanta sashin lafiya cikakken takarda maimakon dogaro da taƙaitaccen bayani.
Kammalawa ga masu son biohacking
CBL‑514 yana da ban sha'awa a fannin biotechnologia: maganin ƙwaya ne da ke nufin sanya ƙwayoyin kitse a wurin da aka yi allura su mutu ta hanyar apoptosis. Bayanai na Phase 2 suna nuna zai iya rage girman kitse a ƙashin ciki fiye da saline, ba tare da wani babban canjin nauyi ba. Wannan shine alamar maganin da aka keɓe don gyaran jiki, ba ƙone kitse ba.
Har yanzu yana bukatar ƙarin gwaje‑gwaje, domin ba a amince da shi ba, kuma ba ƙari ba ne. Ba wani abu ne da za a sayi ko a yi allura da kai ba. Duk wani abu da ake sayarwa a yanar gizo da wannan suna ba tare da shiga gwaji ba ba a san shi ba, kuma tsarin kwayar ba a bayyana ba. Za a buƙaci manyan gwaje‑gwaje masu sa ido, waɗanda suka fi blind, kuma masu tsawon lokaci don tabbatar da ko sakamakon farko na da tasiri.
Majiyar: Gold M, Schlessinger J, Goodman GJ, et al. Efficacy and Safety of CBL‑514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single‑Blind, Placebo‑Controlled Phase II Study. Aesthet Surg J. 2025;45(6):611‑620. PMC12080885 | PMID 40037659 | doi.org/10.1093/asj/sjaf032